Epic Sciences, based in San Diego, has raised $24 million in funding from Deerfield Management, Blue Ox Healthcare Partners, and Arsenal Capital Partners. The biotechnology research company is focused on developing personalized diagnostics to enhance the management and treatment of cancer patients.

Epic Sciences' platform identifies and characterizes rare cells, including circulating tumor cells (CTCs), using non-invasive techniques. By detecting genetic and molecular changes in cancer throughout a patient's journey, the technology helps physicians match patients to targeted therapies and monitor for drug resistance. The company's mission is to improve patient outcomes by providing real-time information to guide treatment choices.

Epic Sciences is already partnering with major cancer centers and leading pharmaceutical companies worldwide. With the new funding, the company aims to commercialize its technology and increase the success rate of cancer drugs in clinical trials.

The personalized approach to cancer management and treatment has the potential to significantly impact the healthcare industry, providing physicians with more effective tools to diagnose and treat patients with cancer. Visit us for more information about their latest funding round: https://founderlodge.com/round/Epic-Sciences-raises-24000000-Unknown-2023-04-17-W-Lloyd-S-MTIyMTQ